The report ” Global Malaria Treatment Market By Drugs Class (Artemisinin-Based Combination Therapies (ACTs), Chloroquine Phosphate, Vaccines and Others), Drugs (Mefloquine, Primaquine Phosphate, Quinine Sulfate, Artemether & Lumefantrine, Mosquirix and Others), Treatment (Medication, Supportive Care, Vaccination and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026″, also the Global malaria treatment market is growing at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing prevalence of malaria in tropical and sub-tropical regions along with the rise in investment from government, public & private organizations for the development of novel drugs.
Request For Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-malaria-treatment-market
The key market players in the global malaria treatment market are Merck & Co., Inc, Sun Pharmaceutical Industries Ltd, Sanofi, GlaxoSmithKline plc, Pfizer Inc, Novartis AG, Mylan N.V, Teva Pharmaceutical Industries Ltd, Baxter, Amyris, Advanz Pharmaceutical, Lannett, Hikma Pharmaceuticals PLC, Zydus Cadila, Amneal Pharmaceuticals LLC, LUPIN, NATCO Pharma Limited, Ipca Laboratories Ltd, Alvogen among others.
Increasing prevalence of malaria in tropical and sub-tropical regions is driving the market growth.
Increased government funding to fight against malaria is accelerating the market growth
Unmet market needs of managing malaria burden around the world is also boosting the market growth
Rise in medical insurance in developing countries is acting as catalyst in the growth of this market
Lack or insufficient healthcare infrastructure in underdeveloped and developing regions is hampering the market growth
Lack of awareness related to symptoms of malaria in developing countries also restricts the market growth
Plasmodium parasites are the main causative reason for malaria infection. When the female Anopheles mosquitoes, already carrying the parasite bites the humans, the parasite is released into the bloodstream than they travel to the liver, where their maturation occurs, before they enter the the bloodstream and begin to infect the RBC. After 48 to 72 hours of infection, the parasites inside the red blood cells multiply, causing the infected cells to burst open resulting in symptoms such as chills, fever and sweating that occur in cycles that last two to three days at a time. According to W.H.O, in 2017 there were an estimated 219 million cases of malaria in 87 countries and deaths stood at 435 000. African Region had the highest prevalent rate of malaria in 2017; the region was home to 92% of malaria cases and 93% of malaria deaths
Key Developments in the Market
In April 2019, La Jolla Pharmaceutical Company received the U.S FDA Breakthrough Therapy designation for LJPC-0118, an investigational drug for the treatment of severe malaria. This designation is a key regulatory milestone for the company and it will help the company to work closely with the U.S FDA for the further development of the drug
In July 2018, GlaxoSmithKline plc received the U.S FDA approval for tafenoquine (Krintafel) for the “radical cure” of Plasmodium vivax malaria in patients aged more than 16 years, who are receiving antimalarial therapy for acute infection. This was the new medicine approved after decades to counter P. vivax malaria relapse and to provide potential treatment for vulnerable patients that need it most
Order a Copy of Global Malaria Treatment Market Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-malaria-treatment-market
Segmentation: Global Malaria Treatment Market
By Drugs Class
Artemisinin-Based Combination Therapies (ACTs)
Artemether & Lumefantrine
By Route of Administration
By Distribution Channel
Middle East & Africa
Rest of Middle East & Africa
Global malaria treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of malaria treatment for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report:
Current and future of global malaria treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents:
Global, By Component
Access Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-malaria-treatment-market
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475